UB Paderborn / Katalog / Suche / in CDI

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low‐grade B‐cell lymphomas

Cancer, 2012-07, Vol.118 (14), p.3538-3548

2012

Link zum Volltext

Verfügbarkeit prüfen

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia

Science translational medicine, 2014-09, Vol.6 (252), p.252ra121

2014

Link zum Volltext

Verfügbarkeit prüfen

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Haematologica (Roma), 2010-02, Vol.95 (2), p.232-240

2010

Link zum Volltext

Verfügbarkeit prüfen

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

Journal of clinical oncology, 2011-03, Vol.29 (7), p.805-813

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

Cancer, 2012-07, Vol.118 (14), p.3556-3564

2012

Link zum Volltext

Verfügbarkeit prüfen

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway

Cancer cell, 2007-09, Vol.12 (3), p.201-214

2007

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

Cancer, 2009-04, Vol.115 (7), p.1381-1394

2009

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors

Journal of clinical medicine, 2020-05, Vol.9 (5), p.1542

2020

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529

The Journal of biological chemistry, 2008-02, Vol.283 (8), p.4652-4657

2008

Link zum Volltext

Verfügbarkeit prüfen

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

Blood, 2007-07, Vol.110 (1), p.360-369

2007

Link zum Volltext

Verfügbarkeit prüfen

Is the Incidence of Heparin-Induced Thrombocytopenia Affected by the Increased Use of Heparin for VTE Prophylaxis?

Chest, 2012-11, Vol.142 (5), p.1175-1178

2012

Link zum Volltext

Verfügbarkeit prüfen

Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?

Leukemia & lymphoma, 2011-06, Vol.52 (6), p.1010-1016

2011

Link zum Volltext

Verfügbarkeit prüfen

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

Bone marrow transplantation (Basingstoke), 2018-07, Vol.53 (7), p.826-831

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of Advanced-Phase Chronic Myeloid Leukemia

Current hematologic malignancy reports, 2015-06, Vol.10 (2), p.173-181

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Blood, 2011-09, Vol.118 (11), p.3096-3106

2011

Link zum Volltext

Verfügbarkeit prüfen

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Blood, 2018-11, Vol.132 (Supplement 1), p.601-601

2018

Link zum Volltext

Verfügbarkeit prüfen

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia

Journal of clinical oncology, 2016-03, Vol.34 (8), p.e68-e69

2016

Link zum Volltext

Verfügbarkeit prüfen

Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate

The oncologist (Dayton, Ohio), 2014-11, Vol.19 (11), p.e14-e14

2014

Link zum Volltext

Verfügbarkeit prüfen

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Cancer, 2017-07, Vol.123 (13), p.2482-2488

2017

Link zum Volltext

Verfügbarkeit prüfen

Temperature and Humidity Effects on Acute Vaso-Occlusive Pain Episodes in Sickle Cell Disease

Blood, 2015-12, Vol.126 (23), p.992-992

2015

Link zum Volltext

Verfügbarkeit prüfen

Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?

Cancer, 2015-03, Vol.121 (6), p.872-875

2015

Link zum Volltext

Verfügbarkeit prüfen

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

Expert review of hematology, 2016-05, Vol.9 (5), p.419-424

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Blood, 2016-12, Vol.128 (22), p.3093-3093

2016

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7007-7007

2015

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7033-7033

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low‐grade B‐cell lymphomas

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors

Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells

Is the Incidence of Heparin-Induced Thrombocytopenia Affected by the Increased Use of Heparin for VTE Prophylaxis?

Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

Management of Advanced-Phase Chronic Myeloid Leukemia

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia

Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Temperature and Humidity Effects on Acute Vaso-Occlusive Pain Episodes in Sickle Cell Disease

Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?

Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions

Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine

Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission

Suchergebnisse filtern